Notice for mogamulizumab (Kyowa Kirin Australia Pty Ltd)
Active ingredients
mogamulizumab
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Solution for IV administration
Indication
For the treatment of cutaneous t-cell lymphoma
Therapeutic area
Haematology